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Sclerosteosis is an autosomal recessive sclerosing bone dysplasia characterized by progressive skeletal overgrowth.
The majority of affected individuals have been reported in the Afrikaner population of South Africa, where a high
incidence of the disorder occurs as a result of a founder effect. Homozygosity mapping in Afrikaner families along
with analysis of historical recombinants localized sclerosteosis to an interval of ∼2 cM between the loci D17S1787
and D17S930 on chromosome 17q12-q21. Here we report two independent mutations in a novel gene, termed
“SOST.” Affected Afrikaners carry a nonsense mutation near the amino terminus of the encoded protein, whereas
an unrelated affected person of Senegalese origin carries a splicing mutation within the single intron of the gene.
The SOST gene encodes a protein that shares similarity with a class of cystine knot–containing factors including
dan, cerberus, gremlin, prdc, and caronte. The specific and progressive effect on bone formation observed in
individuals affected with sclerosteosis, along with the data presented in this study, together suggest that the SOST
gene encodes an important new regulator of bone homeostasis.
Introduction
The term “sclerosteose” or “sclerosteosis” was first ap-
plied by Hausen (1967), who recognized a disorder that
was distinct from osteopetrosis. Sclerosteosis (SOST
[MIM 269500]) is a severe sclerosing skeletal dysplasia
in which massive bone overgrowth throughout life leads
to gigantism, distortion of the facies, and entrapment of
the seventh and eighth cranial nerves. Widening of the
calvarium of the skull causes elevation of intracranial
pressure and predisposes to sudden death from impac-
tion of the brain in the foramen magnum. Syndactyly is
a variable manifestation but represents an important di-
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agnostic feature in infancy. Histological examination of
bone from affected individuals reveals thicker-than-nor-
mal trabeculae and cortices, along with increased bone
density (Epstein et al. 1979; Stein et al. 1983). Detailed
analyses of markers of bone turnover indicate that the
disorder affects bone modeling and remodeling, espe-
cially in the skull and diaphyseal region of the long
bones. Elevated alkaline phosphatase and increased rates
of bone formation suggest a defect in osteoblast func-
tion. Osteoclast function is generally within the normal
range; however, the effect on osteoclast numbers varies.
No endocrinological abnormalities have been noted.
Although the condition is rare, 160 affected persons
have now been documented. The vast majority are pre-
sent in the Afrikaner population of South Africa, in
which the phenotype was essentially delineated and in
which the autosomal recessive disorder was predicted
to be homogeneous (Beighton et al. 1976, 1977; Beigh-
ton and Hamersma 1979; Beighton 1988). Other iso-
lated reports have also emanated from the United States
(Higinbotham and Alexander 1941; Stein et al. 1983),
Switzerland (Peitruschka 1958), Japan (Sigiura and Ya-
suhara 1975), Brazil (Freire de Paes Alves et al. 1982)
and Spain (Bueno et al. 1994).
Sclerosteosis is similar in phenotype to van Buchem
disease, which has been documented in !30 affected
persons worldwide, the majority of whom come from
The Netherlands (van Buchem et al. 1976; Dixon et al.
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Figure 1 Clinical manifestations of sclerosteosis. A, An adult
Afrikaner with the characteristic mandibular overgrowth, facial palsy,
and deafness. B, Lateral radiograph of the skull of an affected adult
Afrikaner. Gross hyperostosis of the calvarium and base are evident.
1982; Fryns and Vandenberghe 1988). Van Buchem dis-
ease differs from sclerosteosis by virtue of milder man-
ifestations and the absence of syndactyly. At the re-
spective ends of the spectrum of severity, however, these
two disorders do share some overlap. The conditions
have been classified together as endosteal hyperostoses,
and the question of syndromic identity has been debated
for many years (Beighton et al. 1984). Since the Afri-
kaner and Dutch populations share ancestral links, it is
possible that these two autosomal recessive disorders
have a fundamental genetic relationship. The gene for
van Buchem disease was mapped to chromosome
17q12-q21 (van Hul et al. 1998); this was followed by
the localization of the sclerosteosis locus to a large over-
lapping region in two unrelated families from Brazil and
the United States, thus adding support to this hypothesis
(Balemans et al. 1999).
We ascertained 22 affected families from the Afri-
kaner population, with common ancestors dating back
to the 17th century. Through homozygosity mapping
and positional cloning, we determined that the genetic
determinant is indeed homogeneous in this population,
and we identified the gene that is mutated in South
Africans as well as in an unrelated affected person of
Senegalese origin. This novel gene encodes a protein
exhibiting striking sequence similarity to a class of se-
creted factors previously shown to act as antagonists of
members of the TGFb superfamily, including bone mor-
phogenetic proteins (BMPs). This sequence similarity
suggests a model for how the sclerosteosis protein,
herein termed “sclerostin,” may function in bone me-
tabolism, which is consistent with the phenotype of scle-
rosteosis. In addition, we discuss the implications of this
finding in relation to the molecular basis of van Buchem
disease.
Material and Methods
Family Material
The majority of the South African families with scle-
rosteosis have been under the care of H.H. for more
than three decades. During this period they have been
assessed and documented by P.B. (in the Department of
Human Genetics, University of Cape Town), and, since
1993, several new kindreds have been identified. Typical
clinical manifestations include distortion of the facies
and mandibular protrusion with entrapment of cranial
nerves causing deafness and facial palsy (fig. 1A). Skel-
etal hyperostosis and sclerosis are evident radiographi-
cally, especially in the calvarium and base of the skull
(fig. 1B). Individuals 1–18 had been previously docu-
mented (Beighton et al. 1976; Beighton and Hamersma
1979), whereas individuals 19–29 are from South Af-
rican families identified more recently (table 1).
After informed consent was obtained, genomic DNA
was isolated from venous blood samples by standard
procedures. A genome scan on pools of DNA isolated
from venous blood was performed as described else-
where (Wildenberg et al. 1995; Wang et al. 1997), using
M13-tailing of forward primers and Li-Cor DNA 400
automated infrared instruments for microsatellite detec-
tion and analysis. We used primers from the high-density
Cooperative Human Linkage Center (Weber version 6)
human genome screening set (Research Genetics) for the
initial scan. The affected Senegalese individual was doc-
umented elsewhere (Tacconi et al. 1998). Genomic DNA
isolated from venous blood was used for direct sequence
analysis. Through M. Hayden, we obtained genomic
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Table 1
Summary of Affected Individuals with Composite of Sclerosteosis
Family Pedigrees
Affected
Individual Kindred Sex Sibship
Parental
Consanguinity
1 A F ● 
2 B F ●● 
3 B F
4 C M  
5 D F ● 
6 D M
7 E F ● 
8 E M 
9 F F ● ?
10 G F ● 
11 H M ● 
12 H F
13 I F ● 
14 I M
15 J F ● 
16 K F ●● 
17 K F
18 L M  
19 M M  ?
20 M M
21 N F ● 
22 O F ● 
23 P F ● 
24 Q M  
25 R F  
26 S M  
27 T F ● 
28 U M  
29 V M  
NOTE.—29 affected individuals from 22 kindreds (A-V) are indi-
cated by blackened symbols, along with their respective unaffected
sibs in unblackened symbols. Circles represent females, squares rep-
resent males. In kindred C, DNA was available for analysis from only
one (individual 4) of two affected brothers.
DNA samples from seven Dutch individuals affected
with van Buchem disease.
Linkage Analysis
Linkage analysis was performed using the FASTLINK
programs (Cottingham et al. 1993; Scha¨ffer et al. 1994).
Two-point linkage analysis between the microsatellite
markers and the disorder was performed using the
MLINK option of the Linkage Analysis Package (version
5.1) (Lathrop and Lalouel 1984) under the assumption
that sclerosteosis is an autosomal recessive disorder with
a disease frequency of 1/50,000. Allele frequencies of the
markers were set at 1/n, where n was the number of
alleles identified in the affected families.
Physical Mapping and Mutation Detection
Bacterial artificial chromosome (BAC) clones were ob-
tained from the California Institute of Technology BACs
(CITB) human BAC B and C libraries (Research Genet-
ics). In most cases, we sequenced directly the ends of
BAC clone inserts by following the protocols for tem-
plate preparation provided by The Institute for Genome
Research (TIGR) and for Big Dye terminator cycle se-
quencing as recommended by PE Applied Biosystems.
Ordering of smaller contigs relative to each other was
greatly aided by mapping of microsatellite markers and
BAC end-derived sequence-tagged sites (STSs) on the
Stanford TNG mapping panel, essentially following the
procedure outlined at the Stanford Human Genome
Center (SHGC) Web site. Clones chosen for sequencing
across the insert were purified over a CsCl gradient,
“shotgun” cloned into M13 or pUC19, and subjected
to Big Dye primer sequencing using ABI 377s. We used
the SPUTNIK program to detect new microsatellite se-
quences, and we used BLAST and GENSCAN (Burge
and Karlin 1997) to identify all candidate genes in the
critical interval. For mutation detection, we used
Primer3 to identify PCR primers flanking each known
and predicted exon to allow amplification and direct
sequencing from genomic DNA. Sequence comparisons
were performed using the Staden XGAP analysis pack-
age. Control DNAs were derived from 48 unrelated,
unaffected South African individuals; the NIGMS Hu-
man Variation Collection, panels HD01–HD09; and the
NIGMS DNA Polymorphism Discovery Resource, pan-
els 1–3. NIGMS DNAs represent 10 different ethnicities
(Coriell Cell Repositories).
In Vitro Splicing Assay
A 4.3-kb EcoRV-XhoI fragment from BAC 202l9
(P50) subcloned into pBSII SK() (Stratagene) served as
template for site-directed mutagenesis (Muta-Gene Kit,
BioRad Corp.) to generate mut1-SOST, mut2-SOST, and
SDmut-SOST. The mutagenic primers were 5′-CTCTC-
CTCCACCCCAAACCTTTGGTCTCAAAGG-3′, 5′-G-
GACCGGCCCGTCGCTCTCCACCCCAGCC-3′, and
5′-CTCTCCTCCACCCCATACATTTGGTCTCAAAG-
GG-3′, respectively (where the underlined bases indi-
cate deviation from the nonmutant sequence). In addi-
tion, the mutagenic primer 5′-CCAGTGGGAGCTGC-
ATGGGCGGCCGCTACCAGCCAGAGGAGG-3′ was
used to introduce a NotI site immediately upstream of
the initiating methionine codon of SOST, so that the
four gene bodies could be subcloned as NotI-XhoI frag-
ments into pPS1286, a mammalian expression vector
containing the Rous Sarcoma virus long terminal repeat
(RSV LTR) and the polyadenylation signal from SV40
(P.J.S.). Transient transfections of COS-1 and CHO cells
with all four constructs were performed by both elec-
troporation and DEAE-Dextran, with similar results.
Two days after transfection, total RNA was isolated
from cells with Tri Reagent (Molecular Research Center,
Inc.). Northern blot analysis was performed using stan-
dard methods and reagents from NorthernMAX-gly kit
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Table 2
Two-Point LOD Scores for Sclerosteosis and
Chromosome 17q12-q21 Markers
MARKER
LOD SCORE AT vp
.00 .05 .10 .20 .30 .40
D17S1299  4.42 3.75 2.30 1.08 .28
D17S951 5.57 4.68 3.83 2.31 1.11 .33
D17S579 5.73 4.92 4.07 2.45 1.14 .29
D17S920 5.34 4.57 3.80 2.34 1.12 .29
D17S791 6.19 5.30 4.38 2.67 1.29 .37
D17S806 6.21 5.16 4.16 2.44 1.13 .30
(Ambion). For RT-PCR analysis, dT-primed first-strand
cDNA was synthesized using SuperScriptII (Gibco BRL),
and subsequent PCR was performed with primers cor-
responding to the first and last predicted exons of
P50gsc3: 5′-CCGGAGCTGGAGAACAACAAG-3′ and
5′-GCACTGGCCGGAGCACACC-3′. To obtain se-
quence of the RT-PCR products, they were purified from
agarose gels by QiaQuick columns (Qiagen) and se-
quenced directly with the same primers used for PCR.
Sequencing SOST Gene Region in van Buchem
Disease Samples
We performed direct sequencing of ∼40 overlapping
amplicons spanning a 22-kb region of genomic DNA
from patients with van Buchem disease, including the
5.0-kb SOST gene body (two exons) as well as ∼12 kb
of 5′ and ∼5 kb of 3′ flanking sequence.
Complete SOST cDNA
We performed RT-PCR on RNA derived from human
whole long bone, peripheral blood lymphocytes (PBLs),
and bone marrow, using primers corresponding to the
first and last GENSCAN-predicted exons—for example,
the primer pair described in the splicing assay above, as
well as the following pair, located at the 5′ and 3′ ends
of the predicted ORF: 5′-ATGCAGTCCCACTGGCCC-
3′ and 5′-CTAGTAGGCGTTCTCCAG-3′. Best results
were obtained with the Advantage GC Genomic kit
(Clontech) with 1 M GC Melt reagent included and the
following conditions: 94C for 3 min, followed by 30
cycles of 94C for 35 s, 65C for 1 min, and 72C for
1 min. Full-length cDNAs were obtained from the Hu-
man Universal cDNA Library (HUCL) (Stratagene) by
screening filters with the following 32g-ATP end-labeled
oligonucleotide: 5′-CCGGAGCTGGAGAACAACA-3′.
SOST Gene Orthologs
We obtained total RNA from cow (Bos taurus) and
vervet monkey (Cercopithecus aethiops) whole long
bone by pulverizing fresh material in liquid nitrogen and
extracting RNA with Tri Reagent (Molecular Research
Center, Inc.). The complete coding region of the vervet
Sost gene was obtained by RT-PCR, using human prim-
ers 5′-CCTCCTCTGGCTGGTACC-3′ and 5′-AAT-
CAAACCACGCGCAGAGG-3′; the majority of the bo-
vine coding region was obtained using human primers
5′-GGCCAGGGGTGGCAGGCGTTC-3′ and 5′-CTAG-
TAGGCGTTCTCCAGC-3′. In both cases, first-strand
cDNA was synthesized with SuperScript II (Gibco BRL),
and the Advantage GC Genomic PCR Kit (Clontech)
with 1 M GC Melt reagent was used for PCR under
the following conditions: 94C for 3 min, followed by
30 cycles of 94C for 35 s, 60C for 35 s, and 72C for
35 s.
Three mouse BACs were isolated from the CITB li-
brary (Research Genetics) by screening with human
primers 5′-GGTGTGCTCCGGCCAGTGC-3′ and 5′-
CTTGAGCTCCGACTGGTTGT-3′, chosen because of
their similarity to a rat expressed sequence tag (EST)
sequence (GenBank accession number AI113131). BAC
clone 15g5 was chosen for random shotgun sequencing;
the mouse genomic sequence was then compared to hu-
man SOST cDNA to identify mouse Sost exons. To ob-
tain a mouse Sost cDNA encoding the entire protein
primers corresponding to the 5′ (5′-ATGCAGCCCT-
CACTAGCCCCG-3′) and 3′ (5′-CTAGTAGGCGTTC-
TCCAGCTCCGCCTGGTT-3′) ends of the predicted
coding exons were used to obtain RT-PCR products
from kidney and heart RNA. The complete rat Sost se-
quence was obtained by RT-PCR from kidney RNA,
using primers 5′-ATGCAGCTCTCACTAG-3′ (found in
EST AI113131) and 5′-TAGGCGCGGGCTCGCTCTA-
3′ (corresponding to sequence immediately downstream
of the mouse Sost termination codon). In both cases, a
High GC PCR kit (Clontech) was used according to the
manufacturer’s recommendations, with the following
PCR conditions: 94C for 3 min, followed by 30 cycles
of 94C for 1 min, 65C for 1 min, and 72C for 2 min.
Real-Time Quantitative RT-PCR
Random-primed first-strand cDNA (SuperScript
Preamplification System, Gibco BRL) was used as tem-
plate in separate-tube amplification reactions. All sam-
ples were run in duplicate in each experiment. For cy-
clophilin expression, we used the TaqMan Pre-Devel-
oped Assay Reagent (PDAR) from ABI Biosystems. For
SOST and DAD1 expression, primers were custom
designed and obtained from ABI Biosystems. SOST
primers were 5′-CGGGCGGAGAACGGA-3′ and 5′-
CGGCCCATCGGTCACGTA-3′, and internal TaqMan
probe was 6FAM-TCGGACACGTCTTTGGTCTC-
AAA-TAMRA; DAD1 primers were 5′-AGGAGTAGG-
AGACTAAAAGAATGTTCACTC-3′ and 5′-GTAAG-
TGCAAATCTGAAGAAAATCCAT-3′, with TaqMan
probe 6FAM-TGTCCAATAAGCTGCCATCTCCAGA-
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Figure 2 Pedigrees of families H and B, showing haplotypes for selected markers at the sclerosteosis locus on chromosome 17q12-21.
Alleles are number coded, and the order of the markers from centromere to telomere is according to the Ge´ne´thon human linkage microsatellite
map (Dib et al. 1996). The blackened bars represent the disease haplotype; unblackened and hatched bars represent nondisease haplotypes and
indicate parent of origin in the offspring. In H-II.1, the recombination event, which marks the centromeric boundary of the sclerosteosis locus,
is shown at marker locus D17S1787. The recombined ancestral haplotype that B-II.1 and B-II.2 have inherited from their father, B-I.1, at
D17S930 marks the telomeric boundary of the locus.
ACTCTT-TAMRA. The TaqMan Universal Master Mix
(ABI Biosystems) was used for all the reaction compo-
nents except primers, probe, and template. The final
primer concentrations were 900 nM, and final probe
concentrations were 50 nM. Cycling conditions were
50C for 2 min, 95C for 10 min, and 40 cycles of 95C
for 15 s and 60C for 1 min. The data were collected
and analyzed by the ABI Prism 7700 Sequence Detection
System Software, version 1.6.4. The quantity (measured
in copies/ml) was determined by the standard curve
method, in which a standard curve generated by serial
dilution (1#, 1:10, 1:100, 1:1,000, and 1:10,000) of
a double-stranded fragment of known concentration was
run with the unknown samples. The quantity of each
unknown was determined by plotting a standard curve
(Threshold Cycle (CT) vs. Starting Quantity) and cal-
culating from the CT of each sample the amount am-
plified. The normalized value was determined by mul-
tiplying the relative quantity of SOST for each sample
by the relative quantity of cyclophilin or DAD for that
sample.
Results
Sclerosteosis Maps to 17q12-q21 in the Afrikaner
Population
A composite of 22 affected Afrikaner families, show-
ing the affected and unaffected members of the sibships,
is presented in table 1, with a summary of relevant family
data. The 22 families are not known to be directly re-
lated; nevertheless, because of the high likelihood that,
in this relatively isolated and homogeneous population,
the condition is the result of a founder mutation, the
technique of homozygosity mapping using pooled DNA
samples was chosen as an appropriate strategy for map-
ping (Lander and Botstein 1987). The availability of a
large number of affected families for molecular analysis,
several of which were consanguineous, increased the
likelihood of a successful outcome.
We used a panel of 391 microsatellite markers to ge-
notype DNA pools derived from affected persons (29
total), obligate heterozygotes, and unrelated unaffected
population-matched controls. Initially, locus D17S1299
exhibited an alteration in allele distribution between the
“affected” pools of DNA and the parent and control
pools. We confirmed this linkage to the long arm of
chromosome 17 by typing individual DNAs with
D17S1299 as well as other closely linked markers such
as D17S951, D17S579, D17S920, D17S791, and
D17S806 (table 2). These preliminary mapping results
(Beighton et al. 1999; see also Gardner 1999) were con-
sistent with the localization of sclerosteosis to 17q12-
q21 in two large families from Brazil and the United
States (Balemans et al. 1999).
Additional markers (Dib et al. 1996) were used to
study historical recombinants on the disease chromo-
somes in the 29 affected homozygotes. Three kindreds
included the most informative recombinants: kindreds
A and H each included affected individuals heterozygous
at D17S1787 but not at D17S1793, placing the gene
distal or telomeric to D17S1787 (individual H-II.1 in
fig. 2), whereas a historical recombination event inher-
ited by sibs B-II.1 and B-II.2 placed the gene proximal
or centromeric to marker D17S930. Kindreds H and B
are presented in figure 2. All 29 affected individuals
shared a common haplotype at the marker loci
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Figure 3 Physical map of the sclerosteosis region. Several microsatellite markers from the 17q12-q21 region (e.g., D17S800, D17S1787,
D17S1793, D17S855, D17S1789, D17S1860, D17S930, and D17S934) were used simultaneously to screen the human CITB B and C BAC
libraries. To resolve discrepancies in marker order observed at the time in publicly available 17q21 maps from the Ge´ne´thon, CEPH, and
GeneBridge Radiation Hybrid mapping efforts, we complemented the construction of BAC contigs with “high-resolution” radiation hybrid
analysis on the Stanford TNG mapping panel (Lunetta et al. 1996), using a number of microsatellite markers and novel STSs derived from
BAC ends. Genetic analysis of affected families localized the sclerosteosis region to the interval between D17S1787 and D17S930 (boxed). The
minimum tiling path across this interval (shown below map) comprised 32 clones; these are labeled according to CITB library ID number, with
the exception of clones labeled “Axxxx,” which represent BAC and PAC sequences available in GenBank at the time (full accession numbers
are in the format of “AC00xxxx”). A subset of known genes we placed in this interval are indicated on the map; the sclerosteosis candidate
gene, SOST, is shown in red and is located within 10 kb of D17S951 on BAC clone 202l9 (lab alias P50). Polymorphic markers are shown in
italics; novel microsatellite markers developed as part of this study that further refined the sclerosteosis critical interval are shown in purple.
The map is oriented from centromere (cen) to telomere (tel).
D17S1793, D17S1789, D17S951, and D17S1860
within the critical region bounded by D17S1787 and
D17S930, an interval of ∼2 cM (Dib et al. 1996) on the
cytogenetic border between the chromosomal bands
17q12–q21.
Identification of Candidate Genes across the
D17S1787–D17S930 Interval
To better characterize the D17S1787–D17S930 in-
terval, we constructed a BAC contig of 3–3.5 Mb, con-
sisting of ∼130 overlapping clones, 32 of which com-
prised the minimum tiling path (fig. 3). We determined
the microsatellite marker order in the 17q12-q21 re-
gion to be D17S1787-D17S1793-D17S1802-D17S932-
D17S902-D17S965-D17S1789-D17S951-D17S1860-
D17S930. In addition, a number of novel microsatellites
allowed us to better define the sclerosteosis critical re-
gion (fig. 3). Through random shotgun sequencing
and more-detailed analysis of BAC clones across the
D17S1787–D17S930 interval, we identified ∼70 known
genes, along with an estimated 75–100 novel genes,
identified either through matching sequences in the Ex-
pressed Sequence Tags database or, in some cases, solely
on the predictions made by the GENSCAN algorithm
(Burge and Karlin 1997).
Nonsense Mutation in Novel Transcript Detected by
Direct Genomic Sequencing
As sequence from the BAC clones became available,
we used PCR amplification and direct sequencing of
known and predicted exons to search for sclerosteosis-
specific polymorphisms. Genomic DNAs from an af-
fected individual, an obligate carrier, and an unrelated
unaffected control individual were used as templates. In
all, we sequenced ∼1,000 known and novel exons. Po-
tential disease-causing polymorphisms were first tested
in all other family members and then, if necessary, in 48
unrelated Afrikaner controls and 90 ethnically diverse
individuals from the NIGMS Human Variation Collec-
tion, by direct sequence analysis. Only one polymor-
phism tested in this way did not occur in the unaffected
population; this single-nucleotide change introduced a
nonsense codon to the coding region of a novel transcript
located on BAC 202l9 (lab alias P50).
The novel variant gene (designated “P50gsc3”) pre-
dicted by GENSCAN was located between markers
D17S951 and D17S1860 (fig. 3 and fig. 4). We found
100% concordance between the polymorphism and the
sclerosteosis chromosome when all 29 affected individ-
uals, 33 obligate carriers, and 24 unaffected siblings
were analyzed, consistent with P50gsc3 being the de-
terminant gene. We also extended our sequence analysis
of unaffected control DNAs to include 270 samples from
the NIGMS DNA Polymorphism Discovery Resource.
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Figure 4 Novel predicted P50gsc3 gene contains distinct disease-specific polymorphisms in affected individuals from South Africa and
Senegal. The novel gene as predicted by GENSCAN (P50gsc3) includes four coding exons; however, corresponding cDNAs obtained from a
number of human tissues differed from the predicted transcript in that they did not include the two internal exons (hatched boxes). Note that
the probability scores assigned by GENSCAN to these two internal exons were only .33 and .59, respectively, compared with a score of .99
assigned to both the first and last exons (solid boxes). The single splice donor/splice acceptor pair seen in RT-PCR products did correspond to
that of the first and last predicted exons (indicated by ]). A single-base substitution located 69 bp downstream of the predicted translation
initiation site (C69T) was found in affected Afrikaners, resulting in termination of translation 23 residues from the amino terminus of P50gsc3.
Genomic DNA from the affected Senegalese individual included two substitutions within intronic sequence, located 3 bp (A3T) and 2,692
bp (A2692C), respectively, downstream of the first splice-donor site. None of these three polymorphisms was found in360 unaffected control
individuals.
In no instance was the “sclerosteosis variant” observed
in any of these control samples. The sclerosteosis-specific
C69T transition resulted in a termination codon 23 res-
idues from the amino terminus of the predicted ORF of
P50gsc3 (fig. 4).
Second Mutation in Sclerosteosis Candidate Gene
Affects Splicing
To confirm the identity of the novel mutated gene as
the sclerosteosis determinant, we analyzed the sequence
of the gene in an unrelated indigenous African person
of Senegalese origin, whose condition of sclerosteosis
had been reported elsewhere to be identical to that found
in affected Afrikaners (Tacconi et al. 1998). Indeed, ge-
notype analysis of this individual revealed a region of
homozygosity across the entire D17S1787–D17S930 in-
terval, although with a haplotype distinct from that of
affected Afrikaners, consistent with localization of the
disorder to this same region. Although no sequence
differences existed in the predicted coding region of
P50gsc3, we did observe two different polymorphisms
in intronic sequences that were homozygous and specific
for the Senegalese individual (fig. 4). One of these (an
ArT substitution) was located at position 3 of an in-
tron (mut1-SOST), whereas the other (an ArC substi-
tution) was located 67 bp upstream of a splice-acceptor
site (mut2-SOST). Neither of these nucleotide differences
existed in the sequence of 360 unaffected control DNAs,
thus raising the possibility that one or both of them
could have a deleterious effect on splicing of the P50gsc3
messenger RNA (Cox et al. 1998; Teraoka et al. 1999).
We designed an in vitro splicing assay to determine
the effect of the Senegalese-specific polymorphisms on
expression of the sclerosteosis candidate gene. A ge-
nomic fragment from BAC P50, which contained the
coding exons of the gene, served as template for site-
directed mutagenesis to introduce either the proximal
intronic polymorphism (mut1-SOST) or the distal in-
tronic polymorphism (mut2-SOST). In addition, a scle-
rosteosis gene in which the first splice-donor site was
mutated from AG/GT to AT/GT (SDmut-SOST) served
as a positive control. The four different SOST gene bod-
ies (parental wild-type subclone [wt-SOST], mut1-SOST,
mut2-SOST, and SDmut-SOST) were then subcloned
into a mammalian expression vector in which the ubiq-
uitous RSV LTR controlled expression of the insert (fig.
5A).
After transient transfection of COS-1 or CHO cells,
total RNA was extracted and analyzed both by northern
blot and by RT-PCR. Northern blot analyses consistently
revealed 110-fold higher levels of transcripts from cells
transfected with wt-SOST and mut2-SOST, as compared
with cells transfected with mut1-SOST and SDmut-
SOST (fig. 5B). The length of these transcripts was ∼2.3
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Figure 5 Proximal Senegalese-specific polymorphism affects processing of P50gsc3 transcript in vitro. A,Mammalian expression constructs
containing the four forms of the P50gsc3 gene body under the control of the RSV 3’LTR are shown: (1) wt-SOST derived from BAC P50; (2)
mut2-SOST, containing the distal A2692C intronic polymorphism; (3) SDmut-SOST, containing a nucleotide substitution at the donor splice
site (G-1T); and (4) mut1-SOST, containing the A3T intronic polymorphism. Nucleotide positions of the three mutants are numbered relative
to the first base of the intron. P50gsc3 coding sequence, including the initiating methionine, is represented by blackened boxes; 3′ UTR (excluding
a polyadenylation signal) is represented by unblackened box; heavy horizontal line corresponds to entire 2758 bp intron; the RSV 3′ LTR and
polyadenylation signal (pA) elements derived from the expression vector are also indicated. B, After transient transfection of COS-1 cells with
the indicated construct, total RNA was recovered and analyzed by northern blot, using a fragment corresponding to the full-length SOST cDNA
as a probe. Shown here is one representative blot (the experiment was repeated in triplicate). The quality and concentration of the RNA samples
were first ascertained by running 1 mg of each sample on a 1% agarose gel (nondenaturing) and staining with ethidium bromide (below northern
blot), then 20 mg of each were used for northern blot analyses. Transcripts deriving from constructs wt-SOST and mut2-SOST were consistently
observed at high levels (lanes 1 and 2) and at a size of ∼2.3 kb, indicative of splicing of the intron as shown in 3A. The faint bands at ∼5 kb
most likely represent low level of unprocessed transcript. Constructs SDmut-SOST and mut1-SOST consistently resulted in 10-fold lower
levels of transcript at a size slightly larger than the processed wt-SOST and mut2-SOST transcripts (lanes 3 and 4). C, When the same RNA
samples were subjected to RT-PCR using primers (small arrows) that span the 2758 bp intron, products derived from both the SDmut-SOST
and mut1-SOST transfections indicated the use of a cryptic splice-donor site located 214 bases 3′ of that seen in the products from the wt-
SOST and mut2-SOST constructs. The sequences at the splice junctions are indicated, the additional 214 bp are shown in gray, and the authentic
exonic sequences are solid boxes.
kb, indicative of a splicing event (an unspliced transcript
would have an expected length of ∼5 kb). We then sub-
jected RNA from the transfectants to RT-PCR, using
primers corresponding to the first and last predicted ex-
ons (fig. 5C); sequence analysis of resulting fragments
showed that, whereas the wt-SOST and mut2-SOST
transcripts used the same splice donor and acceptor as
transcripts in unaffected tissue (see below), both the
mut1-SOST and the SDmut-SOST transcripts used a
cryptic splice donor located 214 bp downstream of the
authentic site (fig. 5C). From these experiments we con-
cluded that the proximal intronic polymorphism (mut1-
SOST) found in the Senegalese individual resulted in the
generation of an improperly spliced message. The rela-
tively low levels of mutant transcripts observed could be
the result of nonsense-mediated mRNA decay, as the
inclusion of intronic sequence introduced an in-frame
nonsense codon (Frischmeyer and Dietz 1999; Hentze
and Kulozik 1999).
The identification of two independent mutations in
the sclerosteosis candidate gene P50gsc3, the first being
a nonsense mutation and the second affecting transcript
processing, led us to conclude that sclerosteosis is the
result of the loss of function of this novel gene product.
In keeping with the interim symbol assigned to the scle-
rosteosis locus in the OMIM database (MIM 269500),
we have designated the gene SOST and will refer to its
product as sclerostin.
SOST Gene Not Mutated in van Buchem Disease
We next asked whether sclerosteosis and van Buchem
disease have a direct genetic relationship. Analysis of
genomic DNA from seven Dutch patients with van
Buchem disease across the D17S1787–D17S930 region
revealed a common disease haplotype (not shown). We
then obtained complete sequence across a 22-kb ge-
nomic region, including the 5-kb SOST gene body, from
one patient, and we did not detect any mutations in the
coding region of SOST. Although five noncoding single-
nucleotide polymorphisms (SNPs) in van Buchem disease
DNA were detected (relative to the sequence of BAC
P50), none fulfilled the criterion for causing the condi-
tion, as they all existed within the NIGMS Human Var-
iation Collection control DNAs. One of these was not
in Hardy-Weinberg equilibrium; the remaining four po-
tential “van Buchem alleles” were present at frequencies
ranging from .12 to .99 and were homozygous in 2
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Figure 6 The SOST gene product is highly conserved across
vertebrate species. The vervet (v), rat (r), and mouse (m) sclerostin
sequences are 98%, 89%, and 88% identical, respectively, to the hu-
man (h) sequence. Conserved residues across all four species are high-
lighted with a black background; residues shared by three species are
highlighted in gray. Putative secretory signal sequence is overlined, and
potential sites for asparagine (N)-glycosylation are underlined.
of 94 unaffected individuals. We therefore have no ev-
idence that the two disorders are due to defects in the
same gene.
The SOST Gene Is Highly Conserved across Vertebrate
Species
We obtained RT-PCR fragments corresponding to the
predicted P50gsc3 ORF from osteoblast, thymus, and
PBL RNA. In addition to analyzing RT-PCR products,
we screened the HUCL library (Stratagene) and isolated
two polyadenylated cDNA clones, which included a
639-bp coding sequence and 47 bp of 5′ and 1615 bp
of 3′ UTR sequence. A 5′ rapid amplification of cDNA
ends (RACE) procedure applied to a human osteoblast
cDNA library failed to identify any additional 5′ se-
quence in the P50gsc3 transcript. The sequence of these
cDNAs and RT-PCR products differed from the original
P50gsc3 GENSCAN prediction in that they did not in-
clude the two internal exons (fig. 4). The single splice
donor–splice acceptor pair seen in the cDNAs, however,
did correspond to that of the first and last predicted
exons.
We next characterized SOST gene orthologs from sev-
eral other vertebrate species, including rat, mouse, vervet
monkey, and cow. BLAST analysis identified two partial
rat ESTs (AI113131 and AI556282). PCR primers cor-
responding to regions of 100% identity between human
and rat SOST identified three mouse BACs, and one of
these was sequenced to completion. On the basis of the
mouse genomic sequence, we then designed primers to
obtain RT-PCR products from various mouse tissues
(e.g., kidney and heart), and found the same exon struc-
ture observed in human cDNAs. The rat coding sequence
was subsequently extended by RT-PCR, using mouse
primers. Primers from immediately upstream and down-
stream of the human SOST gene coding sequence (i.e.,
from the UTRs) amplified vervet cDNA from whole long
bone RNA, and a bovine sequence corresponding to the
most highly conserved portion of the gene was obtained
from kidney RNA. At the amino acid level, the vervet,
rat, and mouse sclerostin sequences were 98%, 89%,
and 88% identical, respectively, to the human sequence
(fig. 6). The partial bovine sclerostin sequence was 94%
identical to the human sequence (not shown).
Expression of the SOST Gene
We examined SOST gene expression in a set of 76
human tissues and cell lines by probing the Multiple
Tissue Expression Array (Clontech) with a fragment cor-
responding to the second exon; aorta and fetal kidney
exhibited the highest levels of expression (not shown).
It is noteworthy, however, that bone-related tissues were
not represented on this array. To examine levels of ex-
pression more quantitatively in tissues including bone,
we used real-time quantitative RT-PCR (ABI 7700 in-
strument). Overall expression of the SOST gene was
relatively low, compared with control genes such as PPI
(cyclophilin) and DAD1, but was significant in whole
long bone, cartilage, kidney, and liver and was detectable
at lower levels in placenta and fetal skin (fig. 7). Semi-
quantitative RT-PCR analyses of a number of mouse
tissues (whole fetus, liver, heart, kidney, brain, thymus,
and whole long bone) gave similar results (not shown).
Analysis of Sclerostin Amino Acid Sequence
Amino acid sequence analysis of the SOST gene prod-
uct revealed the presence of a putative secretion signal
and two N-glycosylation sites (fig. 6), suggesting that
sclerostin is secreted. BLAST analysis of public sequence
and ProDom databases revealed weak but significant
similarity to proteins such as gastric mucin, the beta
subunit of luteinizing hormone, as well as dan and a
protein termed “prdc” (protein related to dan and cer-
berus). In all instances, the region of similarity corre-
sponded to a cysteine-rich region in sclerostin that covers
residues 80–167. Outside this region, the sequence of
sclerostin is unique. Analysis of the Pfam hidden Markov
model database of structural motifs recognized similarity
between the cysteine-rich region of sclerostin and the so-
called cystine-knot motif. Although the percent identity
at the level of primary amino acid sequence was quite
low, the specific pattern of cysteine residues was consis-
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Figure 7 The SOST gene is expressed in a tissue-specific manner. Levels of SOST gene expression were determined using the standard
curve method (separate tube reactions) on an ABI Prism 7700 detection instrument, in which the PPI (cyclophilin) and DAD1 genes served as
endogenous references, and the standard curves were generated from a dilution series of a linear plasmid standard of known concentration.
Standard curves were derived by plotting the threshold cycle (CT) vs. starting quantity, in this case expressed in copies/ml, and raw values for
each of the three genes were then calculated from the CT of each test sample. Mean values from duplicate reactions for SOST, PPI, and DAD1
were used in subsequent calculations. Two independent normalized SOST values were derived from the ratio of raw mean SOST to raw mean
PPI value and raw mean SOST to raw mean DAD1 value, for each tissue sample. Expression in the human tissues indicated are represented
by the raw mean SOST values (open bars), SOST values normalized to PPI (solid bars), and SOST values normalized to DAD1 (gray bars).
tent with sclerostin falling into the class of secreted pro-
teins that contain this structural knot motif, such as the
TGFb superfamily, the Norrie disease protein (NDP), the
mucins, and von Willebrand factor (VWF). In particular,
sclerostin includes the highly conserved CxGxC and
CxC motifs characteristic of growth-factor cystine
knots, as well as appropriate spacing of six conserved
cysteines thought to configure the knot structure (Mei-
tinger et al. 1993; Isaacs 1995). Other features of the
cysteine-rich region of sclerostin indicate that it is most
closely related to the subfamily of cystine knot factors
that includes dan, cerberus, gremlin, prdc, and caronte
(fig. 8).
Discussion
Because of the relative homogeneity of the Afrikaner
population, it had been assumed that individuals af-
fected with sclerosteosis shared a common disease allele.
We therefore used the approach of homozygosity map-
ping (Lander and Botstein 1987) to identify and refine
the sclerosteosis locus in affected families. Subsequent
physical mapping and mutation analysis resulted in the
identification of the determinant gene, which we term
“SOST.” In the present study, we describe two mutations
in this gene: the first, found in affected Afrikaners, is a
nonsense mutation near the amino terminus of the cod-
ing region; the second, in an unrelated Senegalese in-
dividual, alters processing of the SOST transcript. Both
of these mutations are expected to result in a loss of
function of the gene product, sclerostin, which is con-
sistent with the recessive nature of the disorder. The fail-
ure to find either of these mutations in a large number
of control individuals (nonsense mutation absent in
1400 controls; splicing mutation absent in 1300 con-
trols) confirmed their direct association with the disor-
der. Discovery of the molecular basis of sclerosteosis may
now lead to accurate diagnoses, thus representing an
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Figure 8 Sclerostin shares sequence similarity with the dan fam-
ily of proteins. The cysteine-rich region of the SOST gene product
(residues 80–167) is aligned with the analogous regions of proteins
encoded by the humanDAN, CER1 (cerberus),DRM (gremlin), mouse
Prdc, chicken Car (caronte), human NDP, MUC2, VWF, and TGFb2
genes. The six canonical cysteine residues forming the core of the knot
structure, including the CxGxC motif, are numbered 1–6 (highlighted
in black), and cysteines that may be involved in additional stabilizing
disulfide bonds are labeled a–d, according to Meitinger et al. (1993)
(highlighted in gray). Pairwise alignments of the cystine knot motif of
sclerostin to each of these other factors show the following percent
identities and number of gaps: DAN (22%, 10); CER1 (24%, 10);
DRM (20%, 12); Prdc (23%, 12); Car (22%, 10); NDP (18%, 17);
MUC2 (15%, 25); VWF (17%, 22); and TGFb2 (11%, 24).
important advance in the genetic management of this
severe and often fatal condition.
Results presented here fail to resolve the question of
syndromic identity between the similar disorders of scle-
rosteosis and van Buchem disease. The majority of
Dutch patients with van Buchem disease carry a com-
mon disease haplotype, suggesting a single founder mu-
tation in this population (van Hul et al. 1998). Because
of the ancestry of the Afrikaners of South Africa, it was
previously hypothesized that the founder mutation in
this population may have derived from a Dutch van
Buchem disease carrier (Beighton et al. 1984). We have
ruled out this hypothesis by demonstrating that the mu-
tation in affected Afrikaners is not present in Dutch
patients with van Buchem disease. In fact, we found no
disease-causing alterations within a 22-kb region sur-
rounding the SOST gene. The complete understanding
of how the two disorders may be associated must await
the determination of the molecular basis of van Buchem
disease.
In our analysis of the amino acid sequence of the
SOST gene product sclerostin, we noted a cysteine-rich
region. Comparative analysis further revealed similarity
to the so-called dan family of secreted glycoproteins,
which includes dan, cerberus/cer1, gremlin/drm, prdc,
caronte, and dante (Hsu et al. 1998; Pearce et al. 1999).
These factors have been proposed to include a cystine
knot structure, on the basis of their sequence similarity
to the knot structures of TGFb2 (determined by crys-
tallography) and NDP (characterized by molecular
modeling) (McDonald and Hendrickson 1993; Meitin-
ger et al. 1993). The predominant feature of the cystine
knot motif is a conserved set of six cysteine residues,
with the CxGxC and CxC fingerprints defining the sub-
class of growth factor knots (Isaacs 1995). Growth
factors of the TGFb superfamily function as dimers,
mediating a wide variety of biological processes. In ad-
dition, it has been demonstrated that the cystine knots
of TGFbs are released by cleavage of a proprotein pre-
cursor during secretion (Gentry et al. 1988). The pres-
ence of cystine knot domains in dan family proteins
suggests that this subfamily of proteins also functions
as secreted dimers. Indeed, the secretion of dan, cer-
berus, gremlin, and caronte has been well documented
(Belo et al. 1997; Nakamura et al. 1997; Biben et al.
1998; Hsu et al. 1998) and, in the case of Cer1 (mam-
malian homolog of cerberus), dimerization but not pro-
cessing of a proprotein has been reported as well (Biben
et al. 1998; Pearce et al. 1999).
It is interesting to note that members of the dan family
share the ability to antagonize BMP signalling. The BMPs
comprise a large family of cytokines, also belonging to
the TGFb superfamily. Although this family of morpho-
gens was originally identified on the basis of bone-in-
ducing activity (Urist 1965), a number of these factors
have been shown to be critical for very early stages of
embryogenesis and fetal development. Depending on the
localization, concentration and timing of expression of
a particular BMP, the processes of chemotaxis, mitoge-
nesis, differentiation, and apoptosis have all been as-
cribed to this class of proteins (Hogan 1996; Sakou
1998). In addition, the requirement for the coordinated
expression of negative regulators of BMP activity, such
as noggin and chordin, as well as members of the dan
family, has been well described (Harland and Gerhart
1997; Sasai and De Robertis 1997; Hsu et al. 1998).
Although the significance of sequence similarity be-
tween sclerostin and the dan family of proteins awaits
direct biochemical characterization of sclerostin func-
tion, the observed similarity does suggest a model for
the function of the SOST gene product that is consistent
with the phenotype of sclerosteosis—that is, loss of a
negative regulator of a TGFb superfamily member (such
as a BMP) important for postnatal formation of bone
could result in excess bone deposition throughout life.
Interestingly, it has been reported recently that the au-
tosomal dominant disorder Camurati-Engelmann dis-
ease results from mutations in the TGFb1 proprotein
that most likely lead to increased and/or inappropriate
activity of the mature factor (Janssens et al. 2000; Ki-
noshita et al. 2000). This disorder shares many radio-
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graphic features with sclerosteosis, pointing to a shared
or parallel pathway for TGFb1 and SOST signalling.
We view the sclerosteosis mutation as a genetic model
of a potential therapy for conditions characterized by
bone loss, notably osteoporosis. Currently there is no
effective treatment for the restoration of normal bone
mass in individuals with pathologically low skeletal den-
sity, and there is a large unmet need for therapy that can
increase bone deposition in osteoporosis (Rodan and
Martin 2000). The pathogenesis and genetics of scleros-
teosis suggest that inhibition of the SOST gene product
could lead to increased bone density, thus reversing the
effects of this common and debilitating condition.
Note: The SOST gene reported here is identical to
the gene termed “BEER,” which is found in U.S. patent
application PCT/US99/27990.
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